Liver - Original Article

Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity

Volume 29 · Issue 5 Publish Date: September 15, 2018
Full Text PDF
DOI
Aslı Haykır Solay
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Ali Acar
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Fatma Eser
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Ferit Kuşcu
Department of Infection Disease and Clinical Microbiology, Çukurova University School of Medicine, Adana, Turkey
Emin Ediz Tütüncü
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Gülnur Kul
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Gönül Çiçek Şentürk
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Yunus Gürbüz
Department of Infectious Diseaes, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Haykır Solay, A., Acar, A., Eser, F., Kuşcu, F., Tütüncü, E. E., Kul, G., … Gürbüz, Y. (2018). Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity. Turkish Journal of Gastroenterology, 29(5), 561–565. https://doi.org/10.5152/tjg.2018.18032
Full Text Full Text PDF

Abstract

Abstract Background/Aims: Tumor necrosis factor-α (TNF-α) inhibitors and ustekunimab are widely used in autoimmune diseases. It is known that these biological agents cause the reactivation of hepatitis B virus (HBV). There is no standardized strategy to prevent the reactivation in patients with evidence of a previous HBV infection. In our study, anti-HBc IgG-positive patients who received a biological agent were evaluated in terms of HBV reactivation. Materials and Methods: Patients who were followed up for the use of biological agents in our clinic were evaluated retrospectively. Patients with isolated anti-HBc IgG positivity were included in the study. The HBV reactivation data were recorded from the patients’ files retrospectively. Results: Two hundred and seventy-eight patients who received biological treatment were evaluated. Twenty-nine patients with isolated anti-HBc IgG positivity or resolved HBV infection were included in the study. The HBV reactivation was seen in 5 patients (17.2%). Of these patients, 3 were using adalimumab, 1 infliximab, and 1 ustekunimab. It was controlled by antiviral therapy that was started in the early period. Conclusion: Drugs that block TNF-α and ustekunimab cause an increase in viral replication. In literature, the HBV reactivation rate was approximately 1% in HBsAg-negative, anti-HBC IgG-positive cases, whereas it was found to be as high as 17.2% in our study. Patients receiving the immunomodulator therapy should be evaluated for HBV serology before treatment and carefully monitored for HBV reactivation during and after treatment. Cite this article as: Solay AH, Acar A, Eser F, et al. Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity. Turk J Gastroenterol 2018; 29: 561-5.

Most read articles by the same author(s)

Article Info
Published In
Journal Turkish Journal of Gastroenterology
Volume / Issue Volume 29 · Issue 5
Pages 561-565
History
Published Online September 15, 2018
Copyright
Affiliations
Aslı Haykır Solay
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Ali Acar
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Fatma Eser
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Ferit Kuşcu
Department of Infection Disease and Clinical Microbiology, Çukurova University School of Medicine, Adana, Turkey
Emin Ediz Tütüncü
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Gülnur Kul
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Gönül Çiçek Şentürk
Department of Infection Disease and Clinical Microbiology, Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Yunus Gürbüz
Department of Infectious Diseaes, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Cite this Article
Haykır Solay, A., Acar, A., Eser, F., Kuşcu, F., Tütüncü, E. E., Kul, G., … Gürbüz, Y. (2018). Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity. Turkish Journal of Gastroenterology, 29(5), 561–565. https://doi.org/10.5152/tjg.2018.18032
Outlines